Skip to content

Total Assets at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$200.89B+3.7%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$472.67M-26.2%
Nuvation Bio logo
Nuvation BioNUVB
$610.24M+23.9%
Immunome logo
ImmunomeIMNM
$619.79M+80.9%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$997M-13.8%
Erasca, Inc. logo
Erasca, Inc.ERAS
$461.23M-2.1%

Other financials

Income statement

See full
Operating income-$46.1M+30.9%
Net income-$43.3M+32.7%
EPS (diluted)-$0.96+49.5%

Balance sheet

See full
Cash & equivalents$62.1M+24.5%
Total debt$419.0K+204%
Total equity$324.0M+60.0%

Cash flow

See full
Operating cash flow-$41.9M+38.4%

Valuation

See full
Market cap$1.57B+62.1%
Enterprise value$1.51B+65.4%

Returns & leverage

See full
Return on equity-55.2%+8.0pp
Debt / equity0.0×
Current ratio14×-0.4×

Where this comes from

Reported directly by ArriVent BioPharma, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Assets.

The official record: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about ArriVent BioPharma, Inc.'s total assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ArriVent BioPharma, Inc.'s total assets?
ArriVent BioPharma, Inc. (AVBP) reported total assets of $349.3M in Q1 2026.
How has ArriVent BioPharma, Inc.'s total assets changed year-over-year?
ArriVent BioPharma, Inc.'s total assets increased by 62.1% year-over-year, from $215.5M to $349.3M.
What is the long-term trend for ArriVent BioPharma, Inc.'s total assets?
Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s total assets has grown at a 42.9% compound annual growth rate (CAGR), from $163.1M to $333.17M.
What does total assets mean?
The sum of everything the company owns — current assets, property, investments, goodwill, intangibles, and all other assets.